Trusted by 10,000+ Scientists since 2006

Obatoclax mesylate (GX15-070)


Bcl-2 抑制剂

0 Customer Reviews
产品目录号: A10665


产品名 目录号 价格 数量
Obatoclax mesylate 5mg A10665-5
¥ 900.00
Obatoclax mesylate 10mg A10665-10
¥ 1,600.00
Obatoclax mesylate 25mg A10665-25
¥ 3,000.00
Obatoclax mesylate 50mg A10665-50
¥ 5,200.00
Obatoclax mesylate 10mM * 1mL in DMSO A10665-10mM-D
¥ 950.00



Bcl-2 homology domain-3 (BH3) mimetic,antagonize all antiapoptotic Bcl-2 family proteins (average IC50, 3 umol/L), including Mcl-1 (IC50, 2.9 umol/L) and Bfl-1 (IC50, 5 umol/L).

Obatoclax mesylate (GX15-070)




顾客使用 Adooq 产品发表的高质量科研文献
Adooq 顾客使用 Obatoclax mesylate (GX15-070) 发表的文献 (2)
  • Chi-Hung R. Or, .et al. Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells, Int J Mol Sci, 2016, Jan; 18(1): 44 PMID: 28035994
  • P Geserick, .et al. The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin, Cell Death Dis., 2014, 5(9): e1412 PMID: 25210795

Chemical Information

目录号 A10665
Mechanism of action Inhibitor
分子量 413.5
化学分子式 C20H19N3O.CH4O3S
Solubility DMSO>83mg/mL Water<1mg/mL Ethanol<1mg/mL
纯度 >98%
储存方式 at -20°C 2 years
CAS No. 803712-79-0
Synonyms N/A
SMILES code CC1=CC(=C(N1)/C=C/2\C(=C/C(=C\3/C=C4C=CC=CC4=N3)/N2)OC)C.CS(=O)(=O)O
化学名称 2-[2-[(3,5-Dimethyl-1H-pyrrol-2-yl)methylene]-3-methoxy-2H-pyrrol-5-yl]-1H-indole methanesulfonate


Bcl-2 homology domain-3 (BH3) mimetic,antagonize all antiapoptotic Bcl-2 family proteins (average IC50, 3 umol/L), including Mcl-1 (IC50, 2.9 umol/L) and Bfl-1 (IC50, 5 umol/L).
Bcl-2 (Cell-free assay)
0.22 μM(Ki)


Solubility (25°C) * In vitro DMSO 83 mg/mL (200.73 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.


Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 24.18 mL 120.92 mL 241.84mL
0.5 mM 4.84 mL 24.18 mL 48.37 mL
1 mM 2.42 mL 12.09 mL 24.18 mL
5 mM 0.48 mL 2.42 mL 4.84 mL

*The above data is based on the productmolecular weight 413.5. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Biological Activity

Description Obatoclax (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 1/2.
Targets Bcl-2
IC50 0.22 μM (Ki) [1]
In vitro Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. [1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. [2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. [3]
In vivo Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. [1]
Features Obatoclax is a potential first-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant members of the Bcl-2 family of proteins, including the dominant member, Mcl-1.

Protocol(Only for Reference)

Kinase Assay: [1]

Bcl-2 Binding affinity calculation A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. [4] As a control in determining the reliability of the calculation, predicted binding affinities Ki) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.

Cell Assay: [2]

Cell lines Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs)
Concentrations ~10 μM
Incubation Time 48-72 hours
Method Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 104 per well for HMCLs or 5~10 × 103 for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined.

Animal Study: [1]

Animal Models Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used.
Formulation Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 mg/mL mannitol, and 5% dextrose.
Dosages 0.0313, 0.25, 0.5 and 2 mg/kg
Administration Administered intravenously (tail vein) once a day


1. Nguyen M, et al. Proc Natl Acad Sci, 2007, 104(49), 19512-191517.
2. Trudel S, et al. Blood, 2009, 113(2), 299-305.
3. Huang S, et al. Clin Cancer Res, 2009, 15 (1), 150-159.
4. Naim M, et al. J Chem Inf Model, 2007, 47(1), 122-133.

Clinical Trial Information( data from

NCT Number Recruitment Conditions Sponsor
Start Date Phases
NCT00918931 Terminated Leukemia|Systemic Mastocytosis M.D. Anderson Cancer Center|Gemin X 2009-06 Phase 2
NCT00933985 Active, not recruiting Acute Undifferentiated Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma etc. National Cancer Institute (NCI) 2009-06 Phase 1
NCT01150656 Active, not recruiting Leukemia National Cancer Institute (NCI)|Children's Oncology Group 2010-06
NCT01238146 Withdrawn Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma etc. National Cancer Institute (NCI) 2010-10 Phase 1|Phase 2
NCT01563601 Withdrawn Extensive-stage Small Cell Lung Cancer Teva Pharmaceutical Industries|Cephalon 2012-08 Phase 3
Read More

View Related Products By Research Topics

Cat. No.

Product NameSolubility(mg/mL)
A10255ABT-737<1 mg/mL163 mg/mL<1 mg/mL
A10022ABT-263 (Navitoclax)<1 mg/mL195 mg/mL<1 mg/mL
A10665Obatoclax mesylate (GX15-070)<1 mg/mL83 mg/mL<1 mg/mL
A10955TW-37<1 mg/mL115 mg/mL4 mg/mL
A10984VX-765<1 mg/mL102 mg/mL102 mg/mL
A11090PAC-1<1 mg/mL78 mg/mL16 mg/mL
A10491JNJ 26854165<1 mg/mL66 mg/mL2 mg/mL
A11931RITA (NSC 652287)<1 mg/mL115 mg/mL4 mg/mL
A10522Lenalidomide (CC-5013)<1 mg/mL52 mg/mL<1 mg/mL
A10743Pomalidomide (CC-4047)<1 mg/mL55 mg/mL<1 mg/mL
A11163AT-406<1 mg/mL112 mg/mL112 mg/mL
A11002YM15589 mg/mL55 mg/mL6 mg/mL
A10935Tipifarnib (Zarnestra)<1 mg/mL83 mg/mL<1 mg/mL
A10657Nutlin-3<1 mg/mL116 mg/mL116 mg/mL

Ordering online

To place an order online, simply browse to the product you are interested in and click on the 'Add to Cart' button. To complete this process, you will need to confirm the size and quantity of the products that you require.

To complete an order you will need to register using our simple online registration process. We do not share your contact details with any third parties.

When you are ready to check out simply enter your PO number to complete the ordering process. Please ensure that you send us a copy of your PO by fax or email afterwards.  We will then liaise with you or your purchasing department to confirm the order.

Found your products but not ready to order?

Why not use our WishList feature to store lists of products? This convenient feature allows you to manage lists, append notes to products and share lists with co-workers or colleagues.

Ordering offline

You can email or fax us your purchase order and we will place the order for you. You can also phone us to place the order.  Our contact details are:

We require the following information to process your order:
  • The catalog number for each product. 
  • Your email address or fax number. 
  • Your name and telephone number. 
  • Shipping address and billing address.
  • Purchase order numbers.




Similar product(s)

Keywords:购买 Obatoclax mesylate (GX15-070) | Obatoclax mesylate (GX15-070) 供应商 | 订购 Obatoclax mesylate (GX15-070) | Obatoclax mesylate (GX15-070) 价格 | Obatoclax mesylate (GX15-070) 生产商 | 订单 Obatoclax mesylate (GX15-070) | Obatoclax mesylate (GX15-070) 代理商 | 购买 803712-79-0| 803712-79-0 供应商 | 订购 803712-79-0 | 803712-79-0 价格 | 803712-79-0 生产商 | 订单 803712-79-0 | 803712-79-0 代理商|buy Obatoclax mesylate (GX15-070) | Obatoclax mesylate (GX15-070) Supplier | purchase Obatoclax mesylate (GX15-070) | Obatoclax mesylate (GX15-070) cost | Obatoclax mesylate (GX15-070) manufacturer | order Obatoclax mesylate (GX15-070) | Obatoclax mesylate (GX15-070) distributor | buy 803712-79-0| 803712-79-0 Supplier | purchase 803712-79-0 | 803712-79-0 cost | 803712-79-0 manufacturer | order 803712-79-0 | 803712-79-0 distributor